ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Mechanisms involved in the development of cardiotoxicity are based on the inhibition of the main target molecules used to treat CML (inhibition of ABL tyrosine kinase, on-target effects) and other kinases that are not involved in the pathogenesis of the disease (off-target) [16-20].